The Pittsburgh Life Sciences Greenhouse (PLSG), an organization providing capital investments to the western Pennsylvania’s life sciences enterprises, announced that it has recently closed $725,000 in direct company investments.
The investments include:
– $200,000 in NeuroInterventions, Inc., which will support prototyping a family of patent-pending catheters for addressing deep vein thrombosis, carotid stenting, and traumatic brain injury, in addition to stroke.
– $150,000 in Blue Belt Technologies, which will be used to finalize development and prepare for FDA submission of their core product, the Precision Freehand Sculptor, and will provide the resources to help prepare for full market release of our Orthopaedic and Neurosurgical products.
– $150,000 investment in Vytrace, Inc., which will support the development of a system for use in hospital intensive care units (ICU’s) to enable clinicians to continuously monitor the glucose levels of critically-ill patients aimed at maintaining “tight glycemic control” (TGC) of ICU patients while also enabling them to complete a pilot study and obtain the gap analysis of their development process needed to get them to the FDA pathway, and ready for additional financing.
– $125,000 in ThermalTherapeutic Systems, which will support the development of a portable hyperthermic perfusion system capable of delivering heated and unheated fluids at a variety of temperatures used to raise the temperature of the thoracic or peritoneal cavity during hyperthermic and normalthermic perfusion.
– $100,000 investment in Almedtrac, which will assist them with marketing their licensed software, Study360, designed for clinical trials management; providing value-added services to all levels of participants in clinical research.
The Pittsburgh Life Sciences Greenhouse develops investment and business growth programs to increase the linkage between research, technology and commercialization, helping biosciences firms locate, expand or start-up in the region. Since its founding in 2002, the organization has committed $14.7m into 60 life sciences companies, leveraging almost $500m in additional capital for them.